Flossbach Von Storch SE Sells 8,875 Shares of Becton, Dickinson and Company $BDX

Flossbach Von Storch SE reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 7.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 116,897 shares of the medical instruments supplier’s stock after selling 8,875 shares during the period. Flossbach Von Storch SE’s holdings in Becton, Dickinson and Company were worth $17,690,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Imprint Wealth LLC purchased a new position in shares of Becton, Dickinson and Company during the third quarter valued at about $25,000. SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company in the fourth quarter worth about $26,000. Meeder Asset Management Inc. boosted its stake in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 102 shares during the last quarter. Main Street Group LTD bought a new position in Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Finally, Bell Investment Advisors Inc purchased a new position in Becton, Dickinson and Company during the 2nd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 11,779 shares of company stock valued at $1,974,669 over the last ninety days. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Up 3.9%

Shares of NYSE BDX opened at $187.82 on Thursday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.96. The firm has a 50-day simple moving average of $159.86 and a two-hundred day simple moving average of $161.02. The company has a market cap of $51.75 billion, a P/E ratio of 56.57, a PEG ratio of 12.74 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the business posted $3.68 earnings per share. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on BDX shares. Wells Fargo & Company upped their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Royal Bank Of Canada upped their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Barclays increased their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and an average price target of $185.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.